EDAP EDAP TMS SA

EDAP TMS S.A. Confirms Strong Clinical Leadership on HIFU for the Treatment of Localized Prostate Cancer More Than 6,600 Ablatherm Treatments Procedures Performed to date Successful Results at 8 Years to be Presented at the Next European Urology Congress LYON, France, Feb. 24 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP), today confirms its strong clinical leadership on HIFU technology using Ablatherm(R). EDAP continues to validate its clinical leadership position and credibility in the High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer with more than 6,600 Ablatherm treatments performed to date. HIFU is now widely recognized within the medical community as a solution for patients who are not candidates for surgery or who failed radiotherapy treatment. In 2004, more than 20 abstracts referring to the use of HIFU with Ablatherm were presented by Urologists using Ablatherm at various international congresses. Three articles were published in peer reviewed urological journals. For more information, please feel free to visit our web site dedicated to HIFU with Ablatherm http://www.edap-hifu.com/. EDAP continues to build its Ablatherm business and expand its market share while benefiting from the support of key opinion leaders and urologists. In line with the strategy to educate both patients and physicians regarding HIFU with Ablatherm as a successful therapeutic option for patients suffering from prostate cancer, EDAP will be actively participating in the next European Association of Urology (EAU) meeting in Istanbul, Turkey, March 16-19, 2005 (Booth C17). Dr. S. Thuroff, from Harlaching Hospital, Munich, Germany, will be presenting successful clinical results at eight years following Ablatherm treatment. Dr. J. Lunz from Caritas Krankenhaus St Joseph Hospital, Regensburg, Germany, will address the better quality of life obtained following Ablatherm treatment compared to radical surgery. Dr. A. Gelet from Edouard Herriot Hospital, Lyon, France, will present updated results obtained after the use of HIFU with Ablatherm on patients who failed radiotherapy treatment. Three additional abstracts referring to the use of Ablatherm will also be discussed over the course of this conference. Hugues de Bantel, Chief Executive Officer of EDAP TMS, commented: "We are very pleased with the number of HIFU with Ablatherm treatments completed as of the end of 2004. The increasing growth rates in Ablatherm treatment clearly confirm our position as the leading provider in the field of HIFU treatment for prostate cancer. With more than 230,000 new prostate cancer cases diagnosed every year in the United States and more than 250,000 new cases in Europe, our market scope is tremendous. We are positioning EDAP for rapid expansion and market share growth. EDAP's strategy will include the continuing education of both patients and physicians regarding HIFU with Ablatherm treatment options, as well as developing our mobile business by offering a payment per procedure performed model, to doctors and hospitals. We are also enthusiastic about our results obtained on patients who failed radiotherapy treatment. With more than 300 treatments performed to date, HIFU with Ablatherm offers a unique curative option to patients who are facing a therapeutic dead end. EDAP is presently working to offer this solution to a wider range of patients facing similar failures from prior treatment." About EDAP TMS S.A. EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. The company is also developing this technology for the treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL). For more information on the Company, contact the Investor Relations Dept by phone at +33 (0)4 78 26 40 46 or see the Company's Web site at: http://www.edap-tms.com/. This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. DATASOURCE: EDAP TMS S.A. CONTACT: Hugues de Bantel, Philippe Chauveau, or Blandine Confort, all of EDAP TMS S.A., +33-4-78-26-40-46; or Matt Kreps or Geralyn DeBusk, both of Halliburton Investor Relations, +1-972-458-8000, for EDAP TMS S.A. Web site: http://www.edap-tms.com/ http://www.edap-hifu.com/

Copyright